Northwestern Scientists Identify Novel Schizophrenia Biomarker and Peptide Therapy to Reverse Cognitive Dysfunction in Adult Brains

Northwestern researchers find a protein deficiency in schizophrenia patients and develop a peptide injection to fix brain circuits and cognitive symptoms.

By: AXL Media

Published: Mar 23, 2026, 7:04 AM EDT

Source: Information for this report was sourced from [Northwestern University]

Addressing the Cognitive Crisis in Schizophrenia Care

Traditional pharmacological treatments for schizophrenia primarily target "positive" symptoms, such as hallucinations and delusions, but offer little relief for the "negative" cognitive impairments that prevent patients from integrating into society. Disorganized thinking and executive dysfunction often lead to chronic unemployment, homelessness, and increased suicidal ideation. According to Peter Penzes, a professor of neuroscience at Northwestern University Feinberg School of Medicine, the discovery of a specific protein deficiency provides the foundation for a revolutionary treatment strategy. By shifting the focus toward "rewiring" the brain, this research aims to solve the societal challenges faced by the two million people living with the disorder in the United States.

Discovery of the Cacna2d1 Protein Biomarker

By analyzing the cerebral spinal fluid of over 100 participants, researchers identified a previously unknown, freely circulating form of the brain protein Cacna2d1. The study revealed that patients with schizophrenia have significantly reduced levels of this protein compared to healthy controls. This deficiency results in overexcited or overactive brain circuits, which are believed to drive the cognitive symptoms of the disorder. Unlike the subjective diagnostic methods currently used in psychiatry, this protein serves as a concrete biological indicator, similar to how blood sugar is used to monitor diabetes or cholesterol for heart disease.

Synthetic Peptide Therapy and Neural Plasticity

The research team developed a synthetic version of the missing protein, designated SEAD1, and tested it on genetic mouse models of schizophrenia. A single injection was found to correct abnormal circuit activity and the associated behavioral problems. Most importantly, the treatment appeared to reopen a window of "brain plasticity," allowing the adult brain to reform synapses and repair damaged connections. Lead author Marc Dos Santos noted that this lack of plasticity is a primary factor in symptom development, suggesting that reforming these neural connections could also provide therapeutic benefits for other mental health conditions, such as depression.